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Histone deacetylases (HDACs) regulate the acetylation of histones in the control of gene expression. Many
non-histone proteins are also targeted for acetylation, including TGF-β signalling pathway components such
as Smad2, Smad3 and Smad7. Our studies in mouse C3H10T1/2 ﬁbroblasts suggested that a number of TGF-
β-induced genes that regulate matrix turnover are selectively regulated by HDACs. Blockade of HDAC activity
with trichostatin A (TSA) abrogated the induction of a disintegrin and metalloproteinase 12 (Adam12) and
tissue inhibitor of metalloproteinases-1 (Timp-1) genes by TGF-β, whereas plasminogen activator inhibitor-1
(Pai-1) expression was unaffected. Analysis of the activation of cell signalling pathways demonstrated that
TGF-β induced robust ERK and PI3K activation with delayed kinetics compared to the phosphorylation of
Smads. The TGF-β induction of Adam12 and Timp-1 was dependent on such non-Smad signalling pathways
and, importantly, HDAC inhibitors completely blocked their activation without affecting Smad signalling.
Analysis of TGF-β-induced Adam12 and Timp-1 expression and ERK/PI3K signalling in the presence of semi-
selective HDAC inhibitors valproic acid, MS-275 and apicidin implicated a role for class I HDACs.
Furthermore, depletion of HDAC3 by RNA interference signiﬁcantly down-regulated TGF-β-induced Adam12
and Timp-1 expression without modulating Pai-1 expression. Correlating with the effect of HDAC inhibitors,
depletion of HDAC3 also blocked the activation of ERK and PI3K by TGF-β. Collectively, these data conﬁrm
that HDACs, and in particular HDAC3, are required for activation of the ERK and PI3K signalling pathways by
TGF-β and for the subsequent gene induction dependent on these signalling pathways.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
TGF-β is a key regulator of extracellular matrix (ECM) formation
and remodelling. To perform this role TGF-β induces the expression of
integral ECM proteins, proteases, and their inhibitors, such as the
tissue inhibitors of metalloproteinases (TIMPs). Regulation of ECM
breakdown and remodelling is critical in development and morpho-
genesis, as well as in physiological and pathological processes such as
ﬁbrosis, wound healing, tumour metastasis and joint destruction in
arthritis.
TGF-β signalling in mammalian cells is mediated through an
interaction of type I and type II TGF-β receptors (TβR), which upon
ligand binding propagate further signalling to intracellular targets via
their receptor kinase activity. Classically, TGF-β receptor activation
leads to phosphorylation of the R-Smads, Smad2 and Smad3. These
recruit the Co-Smad (Smad4), translocate to the nucleus and, by a
direct binding to cognate Smad-binding elements (SBEs), regulate the
transcription of TGF-β target genes. The inhibitor Smad7 is induced in
response to TGF-β to negatively regulate Smad signalling (Shi and
Massague, 2003). TGF-β can also signal through other pathways such
as the mitogen-activated protein kinase (MAPK) and phosphatidyli-
nositol 3-kinase (PI3K) pathways (Derynck and Zhang, 2003). This
can occur rapidly via association of upstream activators of MAPK
signalling with the TβR, for instance the activation of Ras by Shc
association with TβRI (Lee et al., 2007), or with more delayed kinetics
requiring intermediate Smad-dependent and -independent transcrip-
tion responses and/or autocrine growth factor release (Cho et al.,
2007; Horowitz et al., 2004).
The packaging of eukaryotic DNA into nucleosomes also regulates
gene expression. Nucleosomes are generally considered repressive
to transcription, but one mechanism to overcome this inhibition is
Matrix Biology 29 (2010) 602–612
Abbreviations: HDAC, Histone deacetylase; ERK, Extracellular signal-regulated
kinase; PI3K, Phosphatidylinositol 3-kinase; TGF-β, Transforming growth factor-β;
ECM, Extracellular matrix; TSA, Trichostatin A; ADAM12, A disintegrin and metallo-
proteinase 12; TIMP-1, Tissue inhibitor of metalloproteinases-1; PAI-1, Plasminogen
activator inhibitor-1; MAPK, Mitogen-activated protein kinase; JNK, c-Jun N-terminal
kinase; AP-1, Activator Protein-1; VPA, Valproic acid.
⁎ Corresponding author. Institute of Cellular Medicine, 4th Floor Cookson Building,
Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. Tel.: +44
191 2223850; fax: +44 191 2225455.
E-mail address: d.a.young@ncl.ac.uk (D.A. Young).
0945-053X/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.matbio.2010.05.002
Contents lists available at ScienceDirect
Matrix Biology
j ourna l homepage: www.e lsev ie r.com/ locate /matb io
through the enzymatic modiﬁcation of histones via acetylation
(Kouzarides, 2007; Li et al., 2007). Acetylation is mediated by histone
acetyltransferases (HATs) and occurs on speciﬁc lysine residues on
the N-terminal tails of histones H3 and H4, which is proposed to
loosen the histone:DNA structure allowing access of the transcrip-
tional machinery and binding of acetyl groups by proteins containing
bromo-domains (Clayton et al., 2006). Eleven histone deacetylases
(HDACs) have been characterised which remove these acetyl groups
resulting in hypo-acetylation (de Ruijter et al., 2003; Gregoretti et al.,
2004). Numerous transcriptional activators/co-activators or repres-
sors/co-repressors have been identiﬁed which have (or recruit) HAT
or HDAC activity, respectively. Non-histone substrates of HATs (and
subsequently HDACs) have also been described which include,
amongst others, numerous transcription factors and signalling
pathway proteins (Glozak et al., 2005).
In theory, hyper-acetylation of histones associates with transcrip-
tional activation, and the converse, hypo-acetylation of histones is
associated with transcriptional repression. However, in large scale
gene studies a signiﬁcant number of genes are also down-regulated in
the presence of HDAC inhibitors (Xu et al., 2007). In addition, global
HDAC inhibition with trichostatin A (TSA), a non-selective general
HDAC inhibitor, causes the repression of a subset of TGF-β-induced
genes (Ghosh et al., 2007; Glenisson et al., 2007; Kuang et al., 2007;
Rombouts et al., 2002) and suppresses TGF-β-induced epithelial-to-
mesenchymal transition in human renal epithelial cells (Yoshikawa
et al., 2007). We previously reported that HDAC inhibitors also
repressed TGF-β-induced Timp-1 expression (Young et al., 2005),
providing insight into the mechanisms underlying Timp-1 expression
and offering the opportunity of modulating Timp-1 expression in
pathology. However, the mechanisms of HDAC inhibitor-mediated
repression of TGF-β-induced gene expression remain unclear.
Here we use Timp-1 and another TGF-β-induced gene, the
membrane-bound protease Adam12, both of which are Smad-
dependent but exhibit differences in the non-Smad signalling
elements of their induction, to show that HDAC inhibitors repress
the induction of these genes via regulation of non-Smad signalling
pathways such as the ERK and PI3K pathways. TGF-β-induced Pai-1
expression is also presented as a control gene unaffected by HDAC
inhibitors. RNA interference (RNAi)-mediated depletion demonstrat-
ed that HDAC3 mediates the TGF-β-induced expression of Adam12
and Timp-1, via controlling the level of ERK and PI3K activation.
Overall our data show that HDACs are critically important for gene
induction by TGF-β via the regulation of MAPK and PI3K activation.
2. Results
2.1. Histone deacetylases regulate a subset of TGF-β-induced genes
We used real-time RT-PCR to measure the time-course of Adam12,
Timp-1 and Pai-1 induction by TGF-β in the murine pluripotent
mesenchymal C3H10T1/2 cell line, which has been widely used to
study responses to the TGF-β family of growth factors (Denker et al.,
1995; Wang et al., 1993; Young et al., 2005). Adam12 and Timp-1
induction was a late event, maximal at 8 h (Fig. 1A), and subsequent
experiments were performed at this time-point. We conﬁrmed the
role of Smad signalling in the TGF-β induction of Adam12 and Timp-1
in comparison with Pai-1 by siRNA depletion of both the R-Smads
(Smad2 and Smad3) and the co-Smad, Smad4. Both Adam12 and
Timp-1 inductions by TGF-β were signiﬁcantly reduced when Smad2,
Smad3 or Smad4 were depleted (Fig. 1B). Depletion of Smad RNA
levels was N80% as measured by real-time RT-PCR while immuno-
blotting for Smad2 and Smad4 demonstrated an almost complete loss
of protein (Supp. Fig. 1). Previously, we reported that the HDAC
inhibitor TSA could prevent the induction of Timp-1 by TGF-β in
murine C3H10T1/2 and swiss-3T3 ﬁbroblasts, implicating a role for
HDACs in Timp-1 expression (Young et al., 2005). We conﬁrmed this
result and tested whether Adam12 and Pai-1 were also repressed by
TSA (Fig. 1C). TSA had no effect on the induction of Pai-1 by TGF-β. By
contrast, the TGF-β induction of Adam12, as for Timp-1, was
signiﬁcantly blocked by treatment with TSA. TSA also reduced TGF-
β-induced ADAM12 expression in human dermal ﬁbroblasts and
SW1353 chondrosarcoma cells (Supp. Fig. 2).
2.2. HDAC inhibitors do not signiﬁcantly affect Smad signalling
The induction of Adam12 and Timp-1 by TGF-β is dependent on
Smad signalling. To establish whether the inhibition of TGF-β-induced
gene expression by HDAC inhibitors was mediated by modulation of
Smad signalling we examined the phosphorylation status of Smad2.
Treatment with TSA had no effect on the phosphorylation of Smad2
induced by TGF-β (Fig. 2A). We then examined the effect of TSA on
Smad2/3 nuclear translocation. Treatment with TSA had no signiﬁcant
effect on the accumulation of Smad2/3 in the nucleus after 1 h
treatment with TGF-β (Fig. 2B). To determine if TSAmodulated Smad-
dependent transactivation we transfected cells with Smad3-dependent
CAGA12-luc, or Smad3- and Activator Protein-1 (AP-1)-dependent
3TP-Lux reporter constructs (Dennler et al., 1998; Wrana et al.,
1992). The activity of each promoter was induced by TGF-β after 8 h
(Fig. 2C). TSA had no effect on the transcriptional activity of the
CAGA12-luc construct. By contrast, TSA partially reduced the
transcriptional activity of the 3TP-Lux construct suggesting the AP-1-
responsive component was regulated by HDACs.
2.3. HDAC inhibitors regulate the activation of non-Smad signalling
pathways by TGF-β
The relatively late induction of Timp-1 and Adam12 by TGF-β
implies the genes may not be a direct target of Smads. To determine
which other non-Smad pathways regulated the induction of Adam12
and Timp-1 by TGF-β we used selective pathway inhibitors to the
three MAPK pathways and PI3K/Akt. The induction of Adam12 was
signiﬁcantly dependent on all MAPK pathways and PI3K/Akt (Fig. 3A)
conﬁrming previous reports (Le Pabic et al., 2003, 2005), while Timp-1
required only MAPK signalling for maximal expression and was PI3K-
independent (Fig. 3A). We next characterised the effect of HDAC
inhibitors on the activation of signalling pathways in C3H10T1/2 cells
over a time-course of TGF-β stimulation. TGF-β activated each MAPK
pathway and the PI3K (indicated by Akt phosphorylation) pathway,
with themostmarked activation after 4 h (Fig. 3B). This late signalling
pathway activation appears critical to gene expression since the
addition of the MEK inhibitor U0126 2h after TGF-β stimulation also
inhibited Adam12 and Timp-1 induction (Supp. Fig. 3).
Signiﬁcantly, TSA blocked the late (4 h) activation of ERK and Akt
(Fig. 3C), and Thr308 phosphorylation of Akt was also blocked (data
not shown). TSA is a broad spectrum HDAC inhibitor, whereas a
number of HDAC inhibitors, including VPA and MS-275 are proposed
to be ‘semi-selective’ between HDAC family members (Khan et al.,
2008). We found that VPA, but not MS-275, also blocked ERK and Akt
activation. TSA also down-regulated JNK phosphorylation. We also
examined the phosphorylation status of ERK and Akt substrates to
demonstrate that this loss of activation has a functional effect. TSA and
VPA both blocked the phosphorylation of the ERK substrate p90RSK
and the Akt substrate GSK3β (Fig. 3C). We further examined the effect
of HDAC inhibitors on the ERK pathway by studying the activation of
upstream kinases. TSA and VPA (and to a lesser extent MS-275) also
reduced the levels of c-Raf phosphorylation. We could not detect a
signiﬁcant increase in MEK phosphorylation in response to TGF-β and
therefore any effect of HDAC inhibitors (data not shown). TSA also
reduced the TGF-β induction of a MAPK-responsive reporter plasmid
containing repeats recognised by serum response factor (SRF)
(Fig. 3D), which is activated by ERK and JNK signalling pathways in
response to TGF-β (data not shown and (Whitmarsh et al., 1995)).We
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conﬁrmed that TSA, VPA and MS-275 were all able to increase the
acetylation of histones H3 and H4 (Supp. Fig. 4).
2.4. Class I HDACs regulate Adam12 and Timp-1 expression
With the use of semi-selective HDAC inhibitors we also sought to
identify a particular class or HDAC isoform involved in TGF-β-induced
Adam12 and Timp-1 expression. VPA inhibited Adam12 and Timp-1
expression at 1 mM (Fig. 4A), a concentration at which it is proposed
to be class I HDAC-speciﬁc (Gottlicher et al., 2001; Gurvich et al.,
2004). MS-275 partially inhibited Adam12 expression at 10 µM, again
a concentration at which it is proposed to inhibit class I HDACs (Khan
et al., 2008; Vannini et al., 2004), but did not inhibit TGF-β-induced
Timp-1. Examination of TGF-β-induced ERK and Akt phosphorylation
indicated that the concentrations at which the semi-selective HDAC
inhibitors blocked Adam12 and Timp-1 expression paralleled those
that inhibited ERK and Akt activation (Fig. 4B). To further demonstrate
the role for class I HDACs we showed that apicidin, a class I speciﬁc
HDAC inhibitor at concentrations of 10 µM and below (Khan et al.,
2008), also blocked the TGF-β activation of ERK and Akt and
signiﬁcantly repressed both TGF-β-induced Adam12 and Timp-1
expression (Fig. 4C). There was no repressive effect of these HDAC
inhibitors on Pai-1 expression (Supp. Fig. 5).
2.5. HDAC3 regulates TGF-β-induced gene expression
Treatmentwith a range of semi-selective HDAC inhibitors suggested
that a class I family HDAC was involved in TGF-β-induced gene
expression. To further identify the HDACs involved we depleted each
class I HDAC independently with siRNAs (Supp Fig. 6). Consistent with
the effect of HDAC inhibitors, depletion of each class I HDAC revealed
that HDAC3 was required for the TGF-β induction of both Timp-1 and
Fig. 1. TGF-β induction of Adam12 and Timp-1 is HDAC dependent. (A) C3H10T1/2 cells were stimulatedwith TGF-β1 (2 ng/ml) for the indicated times and gene expression quantiﬁed by
real-time RT-PCR from isolated RNA and normalised to the housekeeping gene 18S (n=3). (B) Cells were transfectedwith Smad2, Smad3 or Smad4 siRNA or non-targeting control siRNA
(25 nM) for 24 h. Cellswere then serum-starved for 16 h and stimulatedwith TGF-β1 (2 ng/ml) for 8 h and gene expression quantiﬁed by real-time RT-PCR and normalised to 18S (n=4).
(C) Cells were stimulated with TGF-β1 (2 ng/ml) for 8 h after treatment with TSA (100 ng/ml) or DMSO (0.01% v/v). Total RNA was isolated and subjected to real-time RT-PCR for the
indicated gene expression normalised to 18S (n=3). Data are presented as fold induction relative to the basal expression and representmean±S.D. (*pb0.01, **pb0.01, ***pb0.001). Data
are representative of three independent experiments.
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Adam12 (Fig. 5A). By contrast, depletion of HDAC3 had no effect on the
induction of Pai-1 expression. To support this result we used an
additional siRNA targeting a different region of the HDAC3 transcript,
which elicited similar levels of HDAC3 depletion (Fig. 6B), and found
that this also repressed TGF-β-induced Timp-1 and Adam12 (Fig. 5B).
2.6. HDAC3 regulates TGF-β-induced non-Smad signalling
Having shown that Adam12 and Timp-1 induction by TGF-β was
HDAC3-dependent, we hypothesised that HDAC3 was required for
TGF-β-induced Adam12 and Timp-1 expression by regulating the
activation of ERK and Akt. siRNA-mediated depletion of HDAC3 also
inhibited the activation of ERK and Akt correlating with the effect on
gene expression (Fig. 6A and B).
2.7. HDAC3 regulates the TGF-β induction of Activator Proteins
We have previously demonstrated that the induction of Timp-1
expression by TGF-β is dependent on the intermediate expression of
immediate early response genes such as the AP-1 transcription factors
(Young et al., 2005).We have also found that the expression of a number
of TGF-β-induced AP-1 proteins is repressed by TSA (Young et al., 2005
and Supp. Fig. 7). Therefore, we sought to determine whether the
induction of AP-1 subunits by TGF-β was also dependent on HDAC3.
Depletion of HDAC3 signiﬁcantly reduced the induction of a number of
AP-1 familymembers, including c-fos, fosb, c-jun, junb and fra-1/2 (Fig. 7).
3. Discussion
We have previously reported the repression of TGF-β-induced
Timp-1 expression by HDAC inhibitors (Young et al., 2005). Here we
sought to establish the mechanism by which HDAC inhibitors repress
gene expression and the identity of the HDACs involved. By
comparing Timp-1 with two other TGF-β-inducible genes, Adam12
and Pai-1, we conﬁrmed that only a subset of genes are repressed by
HDAC inhibitors. As the induction of Adam12 and Timp-1 by TGF-β is
Smad-dependent we ﬁrst studied the effect of TSA on Smad signalling.
Our data examining the expression of the classically Smad-dependent
gene, Pai-1, and the activation of Smad signalling, strongly suggest
that HDAC inhibitors do not mediate their effects on a subset of TGF-β
responsive genes by modulation of the Smad pathway, consistent
with the ﬁndings of Ghosh et al. (2007). In fact, at time-points beyond
1 hwe found that TSA promoted Smad2, 3 and 4 nuclear accumulation
(Supp. Fig. 8), which is consistent with the ﬁndings of Tu and Luo
(2007). However, although CAGA12-luc and Pai-1 expression were
not repressed we cannot completely exclude the possibility that
acetylated nuclear Smad7 is interfering with Smad–DNA complex
formation at our target genes (Zhang et al., 2007).
Fig. 2. HDAC inhibitors do not down-regulate Smad signalling. (A) Cells were stimulated with TGF-β1 (2 ng/ml) for the indicated times after treatment with TSA (100 ng/ml). Cell
lysates were immunoblotted with Smad antibodies. (B) Cells were stimulated with TGF-β1 (2 ng/ml) for 1 h after treatment with TSA (100 ng/ml) or DMSO (0.01% v/v) control.
Nuclear and cytoplasmic extracts were prepared and immunoblotted with the indicated antibodies. (C) Cells were transfected with (i) CAGA12-luc or (ii) 3TP-Lux luciferase
expression vectors for 24 h, serum-starved for 16 h, then stimulated with TGF-β1 (2 ng/ml) for 8 h after treatment with TSA (100 ng/ml) or DMSO (0.01% v/v) control. Luciferase
activity was quantiﬁed from cell lysates and is presented as mean±S.D. (*pb0.05). Data are representative of three independent experiments.
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Fig. 3. HDAC inhibitors regulate the TGF-β activation of signalling pathways. (A) Cells were stimulatedwith TGF-β1 (2 ng/ml) for 8 h after 30 minute pre-treatmentwithMAPK selective
inhibitors U0126 (10 μM), SB203580 (10 μM)or SP600125 (30 μM), or PI3K inhibitor LY294002 (10 µM), with DMSO control (0.1% v/v). RNAwas isolated and gene expression quantiﬁed
by real-time RT-PCR and normalised to the housekeeping gene 18S. Data are presented as fold induction relative to the basal expression and represent mean±S.D. (n=3, *pb0.05,
**pb0.01, ***pb0.001). (B) Cells were stimulatedwith TGF-β1 (2 ng/ml) for the indicated times and cell lysates analysed by immunoblottingwith the indicated antibodies. (C) Cells were
stimulatedwith TGF-β1 (2 ng/ml) for 4 h after treatmentwith TSA (100 ng/ml), VPA (10 mM),MS-275 (1 µM) or DMSO (0.01% v/v). Cell lysateswere immunoblottedwith the indicated
antibodies. (D) Cells were transfected with SRF luciferase expression vector for 24 h, serum-starved for 16 h, then stimulated with TGF-β1 (2 ng/ml) for 8 h after treatment with TSA
(100 ng/ml) or DMSO (0.01% v/v) control. Luciferase activity was quantiﬁed from cell lysates and is presented as mean±S.D. (*pb0.05, ***pb0.001). Data are representative of three
independent experiments.
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In addition to Smad signalling, TGF-β activates a number of
alternative signalling pathways. Indeed, we showed that in addition to
Smad phosphorylation, TGF-β-activated MAPK and PI3K signalling
with a range of kinetics; the transient activation being consistent with
previous observations in C3H10T1/2 cells (Lien et al., 2006). Although
we have conclusively shown that the TGF-β induction of Adam12 and
Timp-1 expression is Smad-dependent, Adam12 induction has also
been shown to require ERK and Akt signalling (Le Pabic et al., 2003,
2005), while Timp-1 induction is reportedly dependent on ERK
activation (Kwak et al., 2006). We used pharmacological inhibitors
to conﬁrm that these signalling pathways are required, and also
provide evidence that p38 and JNK signalling may also be involved,
although concerns about the lack of speciﬁcity of the p38 and JNK
inhibitors must be considered (Bain et al., 2007). The effect on basal
Adam12 and Timp-1 expression may be due to the inhibitors
preventing endogenous TGF-β-activated non-Smad signalling present
between the cells in culture (Supp. Fig. 9). Taken together, these data
indicate the signiﬁcant role of non-Smad signalling in the subset of
TGF-β-induced genes repressed by HDAC inhibitors.
HDAC inhibitors have been found to regulate cell signalling
networks in transformed cells, although many of these studies use a
minimum of 24 hour HDAC inhibitor treatment (Chen et al., 2005;
Fig. 4. HDAC inhibitors differentially effect TGF-β-induced gene expression. Cells were stimulated with TGF-β1 (2 ng/ml) for (A and C) 8 h or (B) 4 h after treatment with the
indicated concentrations of HDAC inhibitors VPA (mM), TSA (ng/ml), MS-275 (µM), or apicidin (µM), with DMSO (0.01% v/v) control. (A and C) Gene expression was measured
by real-time RT-PCR and normalised to 18S. Data are presented as fold induction relative to the basal expression and represent mean±S.D. (n=3, *pb0.05, **pb0.01, ***pb0.001).
(B) Cell lysates were immunoblotted with the indicated antibodies. Data are representative of three independent experiments.
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Fecteau et al., 2002; Kobayashi et al., 2006; Yu et al., 2002). We
demonstrated that HDAC inhibitors reduced the level of both TGF-β-
induced ERK and Akt phosphorylation, and to a lesser extent JNK
phosphorylation. Importantly, our report is the ﬁrst to demonstrate
that HDACs can modulate a number of intracellular signalling
cascades in response to growth factors. This appeared to be a TGF-
β-speciﬁc effect, because in the absence of the growth factor HDAC
inhibitors activated MAPK signalling, as previously noted for VPA
(Michaelis et al., 2006). Furthermore, when examining IL-1 activation
of MAPK we found no repression by TSA, albeit in cultured human
articular chondrocytes (Supp. Fig. 10). The ERK and PI3K/Akt path-
ways are required for the expression of a number of TGF-β-inducible
genes, including collagen and smooth muscle actin which are also
known to be suppressed by HDAC inhibitors (Glenisson et al., 2007;
Rombouts et al., 2002; Yoshikawa et al., 2007). The down-regulation
of signalling pathways that we have identiﬁed would also cause the
repression of these genes.
Signiﬁcantly, the activity of HDAC inhibitors to suppress gene
expression paralleled their respective potency in suppressing signal-
ling. This ﬁnding suggests HDAC inhibitors suppress Adam12 and
Timp-1 expression by down-regulating signalling. Consequently, MS-
275 was unable to suppress gene expression at concentrations which
had no effect on signalling. Furthermore, the more robust TGF-β-
induced Pai-1 expression, potentially a result of its SBE-containing
promoter, is unaffected by HDACi because its induction is not
dependent on ERK and PI3K signalling (Supp. Fig. 11).
Semi-selective inhibition of class I HDACs and RNAi-mediated
depletion of class I HDAC3 reduced expression of Adam12 and Timp-1
Fig. 5.HDAC3 regulates TGF-β-induced gene expression. (A) Cells were transfected with the indicated class I HDAC-targeting siRNAs, non-targeting control siRNA (25 nM), or mock-
transfected with Dharmafect (DF) alone for 24 h, serum-starved for 16 h, then stimulated with TGF-β1 (2 ng/ml) for 8 h. RNA was isolated and gene expression quantiﬁed by real-
time RT-PCR and normalised to 18S. (B) Cells were transfected with the indicated HDAC3-targeting siRNAs (Dh, Dharmacon; Sig, Sigma), non-targeting control siRNA (25 nM) for
24 h or mock-transfected with Dharmafect (DF) alone, serum-starved for 16 h, then stimulated with TGF-β1 (2 ng/ml) for 8 h. Gene expression was quantiﬁed by real-time RT-PCR
and normalised to 18S. Data are presented as fold induction relative to the basal expression and represent mean±S.D. (n=4, *pb0.05, **pb0.01, ***pb0.001). Data are
representative of at least three independent experiments.
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indicating that HDAC3 is critical to gene induction. Depletion of
HDAC3, but not HDAC1 or HDAC2, also prevented the induction of the
c-Jun gene by phorbol 12-myristate 13-acetate (PMA), causing the
suppression of c-Jun target genes such asMMP-1, COX-2 and cyclin D1
(Yamaguchi et al., 2005). HDAC3 exists in different multi-subunit
complexes to the other class I HDACs, including SMRT and N-CoR,
which allows it to associate with class II HDACs 4, 5 and 7 (de Ruijter
et al., 2003; Verdin et al., 2003). Therefore, it cannot be excluded that
class II HDACs are also involved via their association with HDAC3.
Indeed, Glenisson et al. (2007) reported that HDAC4 was required for
TGF-β-induced α-SMA expression by blocking the expression of the
TG-interacting factors (TGIF) inhibitors of TGF-β signalling. However,
we also depleted the class II HDACs and found no effect of silencing
HDAC4 on TGF-β-induced Adam12 and Timp-1 expression nor any
evidence that HDAC inhibitors could induce TGIF expression in
C3H10T1/2 cells, in fact TSA also blocked the induction of Tgif1 and
Tgif2 by TGF-β (Supp. Fig. 12). The effect of HDAC1 depletion on Pai-1
expression may be accounted for by deacetylase-independent func-
tions of HDAC1 related to its presence in large multi-subunit
complexes (de Ruijter et al., 2003; Verdin et al., 2003).
Further demonstrating the link between HDACs and TGF-β-
induced ERK and Akt, we found that HDAC3 was also required for
signalling pathway activation. This suggested for the ﬁrst time that
HDAC3 is required for efﬁcient gene expression via its role in
activating signalling pathways. Previously HDAC3 has only been
recognised for its role in suppressing signalling pathways such as p38,
NF-κB and JAK/STAT (Chen et al., 2001; Mahlknecht et al., 2004; Togi
et al., 2009). We over-expressed active and deacetylase-inactive
forms of HDAC3 in our C3H10T1/2 cells but found no signiﬁcant effect
on the induction of a proximal promoter Timp-1 construct (Supp.
Fig. 13). This may be a consequence of the complex multi-subunit
roles of HDAC3 masking an effect of HDAC3 over-expression or that
the minimal promoter construct of Timp-1 does not contain the
elements regulated by HDAC3.
The effects of inhibition or depletion of HDACs on the ERK and PI3K
pathways may be due to enhanced phosphatase activity or reduced
activation. HDACs may modulate intracellular signalling cascades
through their interaction with protein phosphatases (PP). These
complexes can be disrupted by HDAC inhibitors, releasing the PP to
catalyse Akt dephosphorylation (Chen et al., 2005). We investigated
this mechanism and also found that PP inhibitors could partially
reverse the HDAC-mediated dephosphorylation of ERK and Akt (Supp.
Fig. 14). Acetylation of signalling pathway proteins may account for
the regulation of signalling by HDACs, however, there is no evidence
of acetylation of any members of these kinase cascades. The
acetylation of MAPK phosphatase-1 has been demonstrated, promot-
ing its association with and dephosphorylation of p38 (Cao et al.,
2008), but no inhibition of p38 was found in the present study.
Alternatively, HDAC3 may be involved in the induction of a factor
required for signalling pathway activation and gene expression. The
late activation of ERK and Akt is very likely Smad and new protein
translation dependent; for example, TGF-β induces an autocrine
growth factor or Snail to activate Akt in mesenchymal cells or
epithelial cells, respectively (Cho et al., 2007; Horowitz et al., 2004).
Indeed Smad4 depletion negated the activation of ERK (data not
shown), but we were unable to conﬁrm a requirement for new
protein synthesis as translation inhibitors induced ERK phosphoryla-
tion. The induction of Timp-1 by TGF-β requires new protein synthesis
including the need for AP-1 transcription factors such as c-Fos (Young
et al., 2005). Adam12 also has a partial requirement for new protein
synthesis (Supp. Fig. 15), although no factors have yet been identiﬁed.
We previously showed that the TGF-β induction of c-fos is also
repressed by TSA (Young et al., 2005), and it is suggested that HDAC-
dependent dynamic turnover of histone tail acetylation must occur at
the c-fos promoter for efﬁcient gene expression (Hazzalin and
Mahadevan, 2005). We now show that induction of a number of
AP-1 transcription factors by TGF-β requires HDAC3. Interestingly,
Hazzalin and Mahadevan (2005) demonstrate association of HDAC3
with the c-fos promoter, however, it is as yet unclear how HDACs and
dynamic turnover of acetylation are required for gene expression.
In conclusion, we have shown that the TGF-β induction of Adam12
and Timp-1 requires both the Smad pathway and non-Smad signalling
such as MAPK and PI3K. HDAC inhibitors do not alter the Smad
pathway, but repress TGF-β-induced ERK and PI3K/Akt. HDAC3 is
required for both efﬁcient gene expression and activation of ERK and
PI3K by TGF-β. These data provide further evidence of how the TGF-β
signalling pathway is regulated by HDACs and acetylation, and how a
number of TGF-β-induced genes involved in the remodelling and
regulation of the extracellular matrix are regulated by HDAC
inhibition.
4. Experimental procedures
4.1. Materials
TGF-β1 was obtained from R&D Systems (Abingdon, UK). Primers,
valproic acid (VPA), Bradford assay reagent and dimethyl sulphoxide
(DMSO)were obtained from Sigma Aldrich (Poole, UK). Trichostatin A
(TSA), HDAC inhibitor-1 (MS-275), U0126, SB203580, SP600125,
LY294002, and the protease inhibitor cocktail were obtained from
Fig. 6. HDAC3 regulates TGF-β-induced ERK and Akt activation. (A) Cells were
transfected with the indicated class I HDAC-targeting siRNAs, non-targeting control
siRNA (25 nM) for 24 h, serum-starved for 16 h, then stimulated with TGF-β1 (2 ng/ml)
for 4 h. Cell lysates were immunoblotted with the indicated antibodies. (B) Cells were
transfected with the indicated HDAC3-targeting siRNAs (Dh, Dharmacon; Sig, Sigma) or
non-targeting control siRNA (25 nM) for 24 h, serum-starved for 16 h, then stimulated
with TGF-β1 (2 ng/ml) for 4 h. Cell lysates were immunoblotted with the indicated
antibodies. Data are representative of three independent experiments.
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Calbiochem (Nottingham, UK). Anti-mouse and rabbit secondary
antibodies were obtained from DakoCytomation (Ely, UK). Cells-to-
cDNA II Kit was purchased from Ambion (Huntingdon, UK). Tissue
culture reagents, Minimal Essential Medium (MEM) with Earle's salts
and foetal calf serum (FCS) were obtained from Invitrogen (Paisley,
UK). Reporter lysis buffer and luciferase assay reagent were from
Promega (Southampton, UK).
4.2. Cell culture
Murine C3H10T1/2 ﬁbroblasts were cultured in MEM with Earle's
salts containing 10% FCS, L-glutamine (2 mM), 1% nonessential amino
acids, 100 IU/ml penicillin and 100 μg/ml streptomycin essentially as
previously described (Young et al., 2005). Monolayer cultures were
maintained at 37 °C in a 5% (v/v) CO2 atmosphere. For all experiments,
serum-free conditions used identical medium without FCS.
4.3. cDNA preparation and real-time RT-PCR analysis
C3H10T1/2 cells were plated overnight in 96-well plates at 80–90%
conﬂuence (25,000 cells/cm2) in FCS-containing medium. The cells
were then serum-starved overnight, followed by addition of TGF-β and
inhibitors at the indicated concentrations. After the indicated time
period RNA was isolated via cell lysis, DNase I treated and cDNA was
synthesised with Ambion Cells-to-cDNA II kit using MMLV reverse
transcriptase and random hexamers following the manufacturer's
instructions. TaqMan or SYBR Green real-time PCR was performed as
described previously (Litherland et al., 2008). For TaqMan PCR, primer
and probe sequences were: Adam12: For, 5′-ATCAGTGTCTTCGG-
CGTTCA-3′ and Rev, 5′-GGCAATTCTTCCTGTTGTTACATACC-3′, Probe:
5′-FAM-CCATGCAGTGCCACGGCCG-TAMRA-3′; Timp-1: For, 5′-CATG-
GAAAGCCTCTGTGGATATG-3′ and Rev, 5′-AAGCTGCAGGCACTGATGTG-
3′, Probe: 5′-FAM-CTCATCACGGGCCGCCTAAGGAAC-TAMRA-3′; Pai-1:
For, 5′-CCGTCTCTGTGCCCATGAT-3′ and Rev, 5′-GGCAGTTCCACGACGT-
CATA-3′, Probe: 5′-FAM-CTCAGAGCAACAAGTTCAACTACACTGAGTT-
CACC-TAMRA-3′. For SYBR Green PCR, primer sequences were:
Smad2: For, 5′-CTCTCCTGTTAATCACAGCTTGG-3′ and Rev, 5′-
CAGAATGCAGGTTCCGAGTAA-3′; Smad3: For, 5′-TCCGTATGAGCTTCGT-
CAAA-3′ and Rev, 5′-GGTGCTGGTCACTGTCTGTC-3′; Smad4: For, 5′-
CCGTGGGTGGAATAGCTC-3′ and Rev, 5′-GGTCATCCACACCGATGC-3′;
Hdac1: For, 5′-GGGCAGTGGTGCTAGGAG-3′ and Rev, 5′-TTTTTCCCACG-
CAAATGG-3′; Hdac2: For, 5′-CTCCACGGGTGGTTCAGT-3′ and Rev, 5′-
CCCAATTGACAGCCATATCA-3′; Hdac3: For, 5′-AGAGAGGTCCCGAG-
GAGAAC-3′ and Rev, 5′-CGCCATCATAGAACTCATTGG-3′; Hdac8: For,
5′-GCAGCTGGCAACTCTGATT-3′ and Rev, 5′-GTCAAGTATGTCCAG-
CAACGAG-3′; CyclophilinB: For, 5′-CTTCATAACCACAGTCAAGACCTC-
3′ and Rev, 5′-CTCCACCTTCCGTACCACAT-3′; c-jun: For, 5′-CCAGAA-
GATGGTGTGGTGTTT-3′ and Rev, 5′-CTGACCCTCTCCCCTTGC-3′;
junB: For, 5′-CGTCTACACCAACCTCAGCA-3′ and Rev, 5′-CGGGTAT-
GAGCTCCCAGTC-3′; c-fos: For, 5′-CAGCCTTTCCTACTACCATTCC-3′
and Rev, 5′-ACAGATCTGCGCAAAAGTCC-3′; fosB: For, 5′-GTTCGCA-
GAGAGCGGAAC-3′ and Rev, 5′-GCCTTTTCCTCTTCAAGCTG-3′; fra-1:
F o r , 5 ′ - C C C A G T A C AG T C C C C C T C A - 3 ′ a n d R e v , 5 ′ -
TCCTCCTCTGGGCTGATCT-3′; For both methods, reactions were ampli-
ﬁed in a 96-well optical reaction plate (Applied Biosystems) and
quantiﬁed using an ABI 7900HT real-time PCR system and the
manufacturer's corresponding software (Applied Biosystems). Relative
quantity of mRNAs was calculated using the comparative cycle
threshold method and normalised by 18S, Cyclophilin or Gapdh
(Applied Biosystems) for the amount of RNA input.
4.4. RNA-mediated interference
For siRNA transfection 25 nM siRNA was transfected into 30–40%
conﬂuent C3H10T1/2 cells (10,000 cells/cm2) using Dharmafect™ 1
lipid reagent (Thermo Fisher). Dharmacon siRNA SMARTpools®
(Thermo Fisher Scientiﬁc, Lafayette, Co.) of 4 speciﬁc siRNA duplexes
(total of 25 nM siRNA) were used to target Smad2 (NM_010754
[GenBank], cat: M_040707); Smad3 (NM_016769 [GenBank], cat:
M_040706); Smad4 (NM_008540 [GenBank], cat: M_040687);
HDAC1 (NM_008228 [GenBank], cat: M_040287); HDAC2
(NM_008229 [GenBank], cat: M_046158); HDAC3 (NM_010411
[GenBank], cat: M_043553); HDAC8 (NM_027382 [GenBank], cat:
M_058613). Sigma MISSION® HDAC3 siRNA was also used to target
HDAC3 (cat: SASI_Mm01_00162230). After a 24 hour transfection,
cells were washed in serum-free medium for 16 h prior to the
addition of TGF-β1 (2 ng/ml). Cells were then lysed for immunoblot-
ting (below) or the RNA isolated and reverse transcribed for real-time
RT-PCR. Depletion of gene-speciﬁc mRNA levels was calculated by
comparison of expression levels with cells transfected with 25 nM
siCONTROL (non-targeting siRNA 2, cat. 001210-02; Dharmacon) and
25 nM AllStars Negative Control siRNA (cat: 1027280; Qiagen).
Fig. 7. HDAC3 regulates TGF-β-induced AP-1 expression. Cells were transfected with HDAC3-targeting siRNAs (Dh, Dharmacon; Sig, Sigma) or non-targeting control siRNA (25 nM)
for 24 h, serum-starved for 16 h, then stimulated with TGF-β1 (2 ng/ml) for 3 h. Gene expression was quantiﬁed by real-time RT-PCR and normalised to 18S. Data are presented as
fold induction relative to the basal expression and represent mean±S.D. (n=4, **pb0.01, ***pb0.001). Data are representative of three independent experiments.
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4.5. Immunoblotting
C3H10T1/2 cells were plated overnight at a density of 25,000 cells/
cm2, serum-starved the following day for 16 h overnight then
stimulated as indicated. Following treatment, cell extracts were
prepared as described previously (Litherland et al., 2008). For
extraction of histones, cell extracts were collected in triton extraction
buffer (PBS containing 0.5% Triton-X-100 (v/v), 2 mM PMSF, 0.02%
(w/v) NaN3). After centrifugation, the histones were isolated in 0.2 N
HCl overnight. Lysates were resolved by SDS-PAGE, transferred to
polyvinylidine diﬂuoride (PVDF) membranes (Millipore, Watford,
UK), and subsequently probed using the following antibodies:
phospho-Smad2, phospho-ERK1/2, ERK1/2, phospho-p38, p38, phos-
pho-JNK, JNK, phospho-Akt, Akt, acetyl-histone 3, acetyl-histone 4,
histone 3, histone 4, phospho-c-Raf, phospho-MEK, phospho-GSK3β,
phospho-p90RSK, lamin A/C, Caspase-3, HDAC1, HDAC2, HDAC3 and
HDAC8 from Cell Signaling Technology (Beverly, MA); Smad4 from
Santa Cruz (CA, USA); Smad2/3 from Upstate (NY, USA); GAPDH from
Chemicon (Southampton, UK); acetyl-α-tubulin and α-tubulin from
Sigma Aldrich (Poole, UK).
4.6. Plasmid, transient transfection and reporter gene assays
Cells were seeded overnight in 24-well plates at a density of
10,000 cells/cm2. Cells were then transfected for 24 h in serum-
containing medium with 0.2 μg per well reporter plasmid using
FuGene HD (Roche, Lewes, UK) according to the manufacturer's
instructions. The following day, cells were washed in PBS, incubated
in serum-free medium for 16 h and then stimulated with TGF-β1
(2 ng/ml). Cell extract was collected in reporter lysis buffer (Promega)
and assayed with luciferase assay reagent (Promega) in a Microlumat
PLUS luminometer (Berthold Technologies (U.K.) Ltd., Redbourn, UK).
4.7. Statistical analyses
Statistical differences between sample groups were assessed using
the two-tailed Student's t-test, where *, pb0.05; **, pb0.01; and ***, pb
0.001.
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